Neurology

Medical Management and Standard of Care

At a Glance

Parkinson-dementia complex of Guam has no established treatment that stops the underlying brain changes. Care focuses on comfort, safety, movement, swallowing, breathing, and quality of life, with a team of specialists and early planning around the person's wishes.

Managing Lytico-Bodig (ALS/PDC) requires a shift in how we think about medical treatment. Because there is currently no established disease-modifying treatment that can stop the underlying brain changes, the goal of care is symptomatic and supportive ^[1]^[2].

This means that instead of trying to “fix” the disease, your medical team focuses on maximizing comfort, safety, and quality of life at every stage ^[3]^[4].

The Multidisciplinary Care Team

Because this condition affects movement, memory, and physical strength, a single doctor is rarely enough. The standard of care involves a multidisciplinary team ^[5]^[6].

Neurologist: Ideally one with expertise in movement disorders or motor neuron diseases ^[7].
Physical and Occupational Therapists: To help with mobility and suggest equipment to maintain independence ^[5]^[8].
Speech-Language Pathologist (SLP): Vital for managing changes in speech and evaluating dysphagia (swallowing difficulties) ^[9]^[8].
Palliative Care Team: Specialists in symptom management. They help manage complex issues like pain, sleep, and emotional distress, and their care is compatible with active symptom treatment ^[10]^[4].
Respiratory Therapist: To monitor the strength of the breathing muscles ^[5]^[11].

Managing Movement and Memory

Doctors may try medications used for Parkinson’s or Alzheimer’s, but these are often extrapolated or off-label decisions ^[3].

Levodopa: While it may be offered as a trial for the stiffness and slowness of “Bodig,” its success is highly variable ^[12]^[13].
Dementia Medications: Cholinesterase inhibitors have uncertain benefit in this condition ^[3]^[14].
ALS Treatments: Medications like riluzole or edaravone are established for selected patients with classic ALS, not proven for Guam ALS/PDC ^[15].

Symptom-Specific Support

As the disease progresses, the focus often turns to managing specific, daily challenges ^[3]:

Secretions and Drooling: Anticholinergic drugs or patches may reduce drooling, but they can worsen confusion, urinary retention, constipation, blurred vision, or thick mucus ^[11]. Drooling often reflects impaired clearance rather than excessive saliva production.
Muscle Cramps and Spasms: Targeted treatments can reduce the discomfort of stiff or twitching muscles ^[4].
Nutrition: A gastrostomy tube (PEG tube) can support nutrition or medication delivery, but it does not prevent aspiration and may not align with every patient’s goals ^[5]^[16].

The Role of Palliative Care and Planning

Palliative care is not just for the very end of life; it should ideally begin shortly after diagnosis ^[10]. This team helps you navigate the “big picture” decisions, such as advance care planning ^[17].

Because both physical and cognitive abilities will decline, it is vital to discuss your values—such as noninvasive ventilation, invasive ventilation, and feeding tubes—while you can still participate in the conversation ^[17]^[18]. These discussions ensure that the care provided always aligns with your wishes ^[4]^[11].

Common questions in this guide

Is there a treatment that can stop Parkinson-dementia complex of Guam?

There is currently no established treatment proven to stop the underlying brain changes in Parkinson-dementia complex of Guam. Care is usually symptom-focused and supportive, with goals of improving comfort, safety, function, and quality of life.

Which specialists should care for someone with Lytico-Bodig?

Care for Lytico-Bodig often involves a neurologist with movement-disorder or motor-neuron-disease experience, along with physical and occupational therapists, a speech-language pathologist, respiratory therapist, and palliative care team. Together, these professionals can address movement, memory, swallowing, breathing, safety, and quality-of-life needs.

Can levodopa help the stiffness and slowness caused by Guam ALS/PDC?

A clinician may offer a monitored levodopa trial for stiffness and slowness, but the benefit is unpredictable. The team should define what improvement to look for and review whether the medicine is helping or causing problems.

Are ALS or dementia medicines proven to help Guam ALS/PDC?

Riluzole and edaravone are established for some people with classic ALS, but they have not been proven to treat Guam ALS/PDC. Cholinesterase inhibitors used for dementia also have uncertain benefit in this condition, so medication choices should be reviewed with a specialist.

Can drooling medicines worsen confusion in Lytico-Bodig?

Yes. Anticholinergic medicines or patches may reduce drooling, but they can also worsen confusion, constipation, urinary retention, blurred vision, or thick mucus. Drooling may result from difficulty clearing saliva rather than making too much saliva, so the clinician should weigh benefits and risks.

What should families know about feeding tubes and breathing support?

A PEG feeding tube can provide nutrition or medicines when swallowing is difficult, but it does not prevent food or saliva from entering the airway. Swallowing and breathing should be monitored as Parkinson-dementia complex of Guam progresses, with a speech-language pathologist and respiratory therapist involved when appropriate.

When should palliative care and advance planning begin?

Palliative care can begin soon after diagnosis and can be provided alongside active symptom treatment; it is not only for the end of life. Early conversations can document preferences about feeding tubes, noninvasive ventilation, invasive ventilation, and other care while the person can still participate.

Get notified when new evidence is published on Parkinson-dementia complex of Guam.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

No established disease-modifying treatment stops the underlying brain changes in Parkinson-dementia complex of Guam, so care is primarily symptomatic and supportive.
A coordinated team may include a neurologist, movement-disorder or motor-neuron disease specialist, physical and occupational therapists, a speech-language pathologist, respiratory therapist, and palliative care clinician.
Levodopa may be tried for stiffness and slowness, but benefit varies, while dementia medicines and classic ALS medicines are not proven or have uncertain benefit for Guam ALS/PDC.
A PEG tube can support nutrition or medication delivery but does not prevent aspiration, making swallowing and breathing monitoring important.
Palliative care and advance care planning can start early to align decisions about ventilation, feeding tubes, and other support with the person's wishes.

References (18)

1
Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam.
Verheijen BM, Oyanagi K, van Leeuwen FW
Frontiers in neurology 2018; (9()):173 doi:10.3389/fneur.2018.00173.
PMID: 29615966
2
[Parkinson-dementia and amyotrophic lateral sclerosis association (complex of Guam). Diagnostic challenge, Mexican patient].
Aguilar-Vázquez CA, Gallardo-González LI, Raymundo-Carrillo AD, et al.
Revista medica del Instituto Mexicano del Seguro Social 2023; (61(5)):677-684 doi:10.5281/zenodo.8316479.
PMID: 37773166
3
Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.
Quinn C, Elman L
Continuum (Minneapolis, Minn.) 2020; (26(5)):1323-1347 doi:10.1212/CON.0000000000000911.
PMID: 33003004
4
Embedded Palliative Care for Amyotrophic Lateral Sclerosis: A Pilot Program and Lessons Learned.
Fahrner-Scott K, Zapata C, O'Riordan DL, et al.
Neurology. Clinical practice 2022; (12(1)):68-75 doi:10.1212/CPJ.0000000000001124.
PMID: 36157626
5
Care management in amyotrophic lateral sclerosis.
Soriani MH, Desnuelle C
Revue neurologique 2017; (173(5)):288-299 doi:10.1016/j.neurol.2017.03.031.
PMID: 28461024
6
Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis.
de Almeida FEO, do Carmo Santana AK, de Carvalho FO
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(3)):911-923 doi:10.1007/s10072-020-05011-2.
PMID: 33443670
7
Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.
Oh J, Kim JA
Journal of clinical nursing 2017; (26(23-24)):4129-4152 doi:10.1111/jocn.13945.
PMID: 28681543
8
Exploring Advancements in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review of Current Modalities and Future Prospects.
Hoxhaj P, Hastings N, Kachhadia MP, et al.
Cureus 2023; (15(9)):e45489 doi:10.7759/cureus.45489.
PMID: 37868386
9
Accessing and Receiving Speech-Language Pathology Services at the Multidisciplinary Amyotrophic Lateral Sclerosis Clinic: An Exploratory Qualitative Study of Patient Experiences and Needs.
Huynh A, Adams K, Barnett-Tapia C, et al.
Journal of speech, language, and hearing research : JSLHR 2024; (67(10S)):4025-4037 doi:10.1044/2023_JSLHR-23-00087.
PMID: 37678221
10
Top Ten Tips Palliative Care Clinicians Should Know About Amyotrophic Lateral Sclerosis.
Everett EA, Pedowitz E, Maiser S, et al.
Journal of palliative medicine 2020; (23(6)):842-847 doi:10.1089/jpm.2020.0046.
PMID: 32101493
11
Respiratory Failure in Amyotrophic Lateral Sclerosis.
Niedermeyer S, Murn M, Choi PJ
Chest 2019; (155(2)):401-408 doi:10.1016/j.chest.2018.06.035.
PMID: 29990478
12
A migration case of Kii amyotrophic lateral sclerosis/parkinsonism dementia complex with the shortest stay in the endemic area and the longest incubation to develop the disease.
Tsunoda K, Yamashita T, Shimada H, et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2017; (46()):64-67 doi:10.1016/j.jocn.2017.08.057.
PMID: 28890043
13
Clinical varieties and epidemiological aspects of amyotrophic lateral sclerosis in the Caribbean island of Guadeloupe: A new focus of ALS associated with Parkinsonism.
Lannuzel A, Mecharles S, Tressières B, et al.
Amyotrophic lateral sclerosis & frontotemporal degeneration 2015; (16(3-4)):216-23 doi:10.3109/21678421.2014.992026.
PMID: 25646866
14
Amyotrophic lateral sclerosis: a clinical review.
Masrori P, Van Damme P
European journal of neurology 2020; (27(10)):1918-1929 doi:10.1111/ene.14393.
PMID: 32526057
15
Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
Barp A, Gerardi F, Lizio A, et al.
Expert opinion on emerging drugs 2020; (25(2)):145-164 doi:10.1080/14728214.2020.1769067.
PMID: 32456491
16
Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date.
Štětkářová I, Ehler E
Diagnostics (Basel, Switzerland) 2021; (11(2)) doi:10.3390/diagnostics11020231.
PMID: 33546386
17
Advance care planning in progressive neurological diseases: lessons from ALS.
Seeber AA, Pols AJ, Hijdra A, et al.
BMC palliative care 2019; (18(1)):50 doi:10.1186/s12904-019-0433-6.
PMID: 31196046
18
What do people affected by amyotrophic lateral sclerosis want from health communications? Evidence from the ALS Talk Project.
Genuis SK, Luth W, Bubela T, Johnston WS
Muscle & nerve 2023; (68(3)):286-295 doi:10.1002/mus.27935.
PMID: 37462337

This page is for informational purposes only and does not constitute medical advice about Parkinson-dementia complex of Guam. A neurologist and the broader care team should tailor medicines, equipment, swallowing and breathing support, and advance-care planning to the individual.

Guide Contents